Association of Persistent Pulmonary Hypertension in Infants With the Timing and Type of Antidepressants In Utero
Open Access
- 1 December 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (12) , e2136639
Abstract
Antidepressant exposure during pregnancy has been linked to increased risk of persistent pulmonary hypertension of the newborn (PPHN).1 Risks of PPHN have been explored for different types of selective serotonin reuptake inhibitors (SSRIs). However, risks after non-SSRI exposure and risks with timing of exposure in pregnancy across type of antidepressants have been insufficiently quantified or evidence remains conflicting.2,3 Given that PPHN is a potentially lethal complication, more detailed information on trimester- and antidepressant type–specific risk is essential.Keywords
This publication has 5 references indexed in Scilit:
- Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysisAmerican Journal of Obstetrics and Gynecology, 2019
- The Danish National Patient Registry: a review of content, data quality, and research potentialClinical Epidemiology, 2015
- Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysisBMJ, 2013
- The Danish National Prescription RegistryScandinavian Journal of Public Health, 2011
- Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the NewbornNew England Journal of Medicine, 2006